The gold layer facilitates linking to the tumor-specific antibody, in this case, mAb 201b. Mouse model showed high targeting efficiency and 73 % reduction in cell colonies in the lung. Over 90% of Bi213 was contained 24 hours after injection.
Presented by: Charles Maitz, PhD, Assistant Professor of Radiation Oncology, University of Missouri, College of Veterinary Medicine and Surgery, Columbia, Missouri, United States
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada